No Data
Xi'an international medical investment (000516.SZ): The maximum number of inpatient beds at Xi'an High-tech hospital has reached 1,680.
Gelonghui December 4th | Xi'an International Medical Investment (000516.SZ) stated in recent investor relations activities that recently, the maximum daily inpatient bed capacity of Xi'an Gaoxin Hospital has reached 1680 beds; the maximum daily inpatient bed capacity of the North and South campuses of Xi'an International Medical Investment Hospital has reached 3880 beds.
China Merchants Securities: Establishment of prepayment policy for medical insurance funds, releasing incremental signals at the bottom of the pharmaceutical sector.
It is reported that standardized prepayment process management, with the scale of regional prepayment in line with the approved standards for about one month, the prepayment system effectively alleviates the financial pressure of medical institutions, empowering the medical and pharmaceutical industry.
International Medicine: third quarter report 2024
xi'an international medical investment (000516.SZ): a net loss of 0.212 billion yuan in the first three quarters.
GeLongHui on October 24th, xi'an international medical investment (000516.SZ) announced its third-quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 3.606 billion yuan, a year-on-year increase of 7.85%; net income attributable to shareholders of the listed company was a loss of 0.212 billion yuan, a year-on-year increase of 4.59%; net income after deducting non-recurring gains and losses was a loss of 0.22 billion yuan, a year-on-year increase of 37.20%; basic earnings per share was -0.0954 yuan per share.
Obesity affects employment, eli lilly and co will try to use weight loss drugs to address the issue of unemployment in the united kingdom.
Peking time on the evening of the 15th, usa pharmaceutical giant eli lilly and co signed a major investment agreement with the united kingdom to explore the use of weight-loss drugs to curb unemployment. The weight-loss treatment company and the developer of the Zepbound drug announced on Monday that it will invest 0.279 billion british pounds (approximately 0.364 billion us dollars) to help address a major health challenge in the united kingdom—obesity, of course, being among them. The strategic cooperation between eli lilly and co and the UK Department of Health and Social Care (DHSC) and the Department of Science, Innovation and Technology (DSIT) is the first.
xi'an international medical investment (000516.SZ): accumulated repurchase of 0.4865% of the company's shares.
Gelonghui October 8 | xi'an international medical investment (000516.SZ) announced that as of September 30, 2024, the company has cumulatively repurchased 10,997,100 shares of the company through the Shenzhen Stock Exchange trading system through centralized bidding trading, accounting for 0.4865% of the company's current total share capital, with a highest fill price of 5.618 yuan/share, a lowest fill price of 4.61 yuan/share, and a total fill amount of 57,426,831.72 yuan (excluding transaction costs).
No Data
